---
layout: default
title: Scopolamine
description: "Scopolamine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 6 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 155
evidence_level: L5
indication_count: 6
---

# Scopolamine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>6</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Scopolamineï¼šå¾è§£ç—™åŠ‘åˆ°ç¥ç¶“åŠçœ¼ç§‘ç–¾ç—…æ¢ç´¢

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Scopolamine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Scopolamine ä¸»è¦ç”¨æ–¼èƒƒè…¸é“ã€è†½é“åŠå°¿è·¯ç—™æ”£çš„ç·©è§£ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**é¦¬å°¾ç—‡å€™ç¾¤ (Cauda Equina Syndrome)** åŠ**ç¥ç¶“æºæ€§è†€èƒ±**æœ‰æ•ˆï¼Œ
ä½†ç›®å‰ç¼ºä¹è‡¨åºŠè©¦é©—åŠæ–‡ç»æ”¯æŒé€™äº›æ–°é©æ‡‰ç—‡ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | èƒƒè…¸ç—™æ”£ã€è†½ç®¡ç—™æ”£ã€å°¿è·¯ç—™æ”£ã€å¥³æ€§ç”Ÿæ®–å™¨ç—™æ”£ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | irritable bowel syndromeã€cauda equina syndromeã€obsolete neurogenic bladder (disease)ã€papillary conjunctivitisã€atopic conjunctivitisã€rosacea conjunctivitis |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.99% |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 317 å¼µ |
| å»ºè­°æ±ºç­– | Hold |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. cauda equina syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Scopolamineï¼ˆæ±è¨èªé¹¼ï¼‰æ˜¯ä¸€ç¨®æŠ—è†½é¹¼è—¥ç‰©ï¼Œä½œç‚ºæ¯’è•ˆé¹¼å—é«”æ‹®æŠ—åŠ‘ï¼Œ
èƒ½æŠ‘åˆ¶å‰¯äº¤æ„Ÿç¥ç¶“æ´»å‹•ï¼Œé”åˆ°è§£ç—™åŠæ¸›å°‘åˆ†æ³Œçš„æ•ˆæœã€‚

**TxGNN é æ¸¬çš„æ–°é©æ‡‰ç—‡èˆ‡æ©Ÿè½‰é—œè¯æ€§åˆ†æï¼š**

| æ’å | é æ¸¬é©æ‡‰ç—‡ | é æ¸¬åˆ†æ•¸ | TxGNN æ’å | æ©Ÿè½‰é—œè¯æ€§ |
|------|-----------|---------|-----------|----------|
| 1 | Cauda Equina Syndromeï¼ˆé¦¬å°¾ç—‡å€™ç¾¤ï¼‰ | 99.99% | 548 | å¯èƒ½ç·©è§£ç¥ç¶“å£“è¿«å¼•èµ·çš„è†€èƒ±ç—™æ”£ |
| 2 | Neurogenic Bladderï¼ˆç¥ç¶“æºæ€§è†€èƒ±ï¼‰ | 99.98% | 909 | æŠ—è†½é¹¼ä½œç”¨å¯ç·©è§£è†€èƒ±éå‹• |
| 3 | Papillary Conjunctivitisï¼ˆä¹³é ­ç‹€çµè†œç‚ï¼‰ | 99.98% | 1,025 | é—œè¯æ€§ä¸æ˜ç¢º |
| 4 | Atopic Conjunctivitisï¼ˆç•°ä½æ€§çµè†œç‚ï¼‰ | 99.80% | 4,736 | é—œè¯æ€§ä¸æ˜ç¢º |
| 5 | Rosacea Conjunctivitisï¼ˆé…’ç³Ÿçµè†œç‚ï¼‰ | 99.40% | 11,144 | é—œè¯æ€§ä¸æ˜ç¢º |
| 6 | Vernal Conjunctivitisï¼ˆæ˜¥å­£çµè†œç‚ï¼‰ | 99.08% | 15,822 | é—œè¯æ€§ä¸æ˜ç¢º |

é¦¬å°¾ç—‡å€™ç¾¤åŠç¥ç¶“æºæ€§è†€èƒ±çš„é æ¸¬è¼ƒç‚ºåˆç†ï¼Œå› ç‚º Scopolamine çš„æŠ—è†½é¹¼ä½œç”¨å¯ç·©è§£è†€èƒ±éå‹•åŠç—™æ”£ç—‡ç‹€ã€‚
ç„¶è€Œï¼Œçµè†œç‚ç›¸é—œé æ¸¬èˆ‡å·²çŸ¥æ©Ÿè½‰é—œè¯æ€§è¼ƒå¼±ã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡é‡å°é æ¸¬é©æ‡‰ç—‡çš„ç›¸é—œè‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

ç›®å‰ç„¡é‡å°é æ¸¬é©æ‡‰ç—‡çš„ç›¸é—œ PubMed æ–‡ç»ã€‚

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. obsolete neurogenic bladder (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. papillary conjunctivitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. atopic conjunctivitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.80%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. rosacea conjunctivitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.40%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.40%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. vernal conjunctivitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.08%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.08%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ | ç‹€æ…‹ |
|---------|------|------|-----------|------|
| å…§è¡›è—¥è£½å­—ç¬¬000509è™Ÿ | ä¿è³œåº·è† å›Š | è† å›ŠåŠ‘ | èƒƒæ½°ç˜ã€è†½å›Šç‚ã€è†½çµçŸ³ã€å°¿è·¯çµçŸ³ã€è†€èƒ±ç—™æ”£ã€ç—™æ”£æ€§æœˆç¶“å›°é›£ç­‰ | æœ‰æ•ˆ |
| å…§è¡›è—¥è£½å­—ç¬¬002211è™Ÿ | å¼·ç”Ÿèˆ’èƒƒç³–è¡£éŒ 10æ¯«å…‹ | éŒ åŠ‘ | èƒƒç‚ã€è…¸ç–ç—›ã€è†½ç®¡ç—™æ”£ã€è†½çŸ³ç–ç—› | æœ‰æ•ˆ |
| å…§è¡›è—¥è£½å­—ç¬¬009840è™Ÿ | å‹¿è³œç—›æ³¨å°„æ¶² | æ³¨å°„åŠ‘ | è…¸ç–ç—›ã€è†½ç®¡ç—™æ”£ã€è†½çŸ³ç–ç—›ã€ç—™æ”£æ€§æœˆç¶“å›°é›£ç—‡ | æœ‰æ•ˆ |
| å…§è¡›è—¥è£½å­—ç¬¬010222è™Ÿ | å—å…‰èƒƒä½¿å¯èƒ–æ³¨å°„æ¶² | æ³¨å°„åŠ‘ | èƒƒè…¸ç—™æ”£ã€è†½ç®¡ç—™æ”£ã€å°¿è·¯ç—™æ”£ã€å¥³æ€§ç”Ÿæ®–å™¨ç—™æ”£ | æœ‰æ•ˆ |
| å…§è¡›è—¥è£½å­—ç¬¬001758è™Ÿ | æ”£æ€•æ–¯ç³–è¡£ç‰‡ | ç³–è¡£éŒ  | èƒƒè…¸ç—™æ”£ã€è†½ç®¡ç—™æ”£ã€å°¿è·¯ç—™æ”£ | æœ‰æ•ˆ |

## å®‰å…¨æ€§è€ƒé‡

- **ä¸»è¦è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆé‡å¤§ï¼‰**ï¼š
  - Topiramateã€Zonisamideï¼šå¯èƒ½å¢åŠ é«”æº«èª¿ç¯€éšœç¤™é¢¨éšª

- **ä¸­åº¦è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
  - é´‰ç‰‡é¡è—¥ç‰©ï¼šFentanylã€Morphineã€Codeineã€Hydrocodoneã€Tramadolã€Buprenorphine ç­‰
  - æŠ—è†½é¹¼è—¥ç‰©ï¼šAtropineã€Hyoscyamineã€Glycopyrroniumã€Benzatropine ç­‰
  - æŠ—ç²¾ç¥ç—…è—¥ç‰©ï¼šAripiprazoleã€Asenapineã€Brexpiprazole ç­‰
  - æŠ—çµ„ç¹”èƒºè—¥ç‰©ï¼šChlorpheniramineã€Brompheniramine ç­‰
  - ä¹™å‹é˜»æ–·åŠ‘ï¼šAtenololã€Bisoprololã€Acebutolol ç­‰
  - å…¶ä»–ï¼šEthanolã€Amantadineã€Amitriptylineã€Loperamide

- **è¼•åº¦è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
  - Acetaminophenã€Hydrochlorothiazide

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šUse of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be...
- å»ºè­°ï¼šAlcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect the...

**é£Ÿç‰© (food)** ğŸ”´ Major
- å½±éŸ¿ï¼šThe coadministration with grapefruit juice may delay the absorption and increase the bioavailability of oral scopolamine.  The proposed mechanism is delay of gastric emptying as well as inhibition of ...
- å»ºè­°ï¼šBased on these findings, grapefruit juice is unlikely to affect the overall safety of scopolamine, but may delay its onset of action after oral administration. Therefore, we recommend taking scopolami...



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é«˜è¡€å£“ (Hypertension)** ğŸ”´ Major
- Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.

**ç”²ç‹€è…ºæ©Ÿèƒ½äº¢é€² (Hyperthyroidism)** ğŸ”´ Major
- In general, agents with anticholinergic activity may exacerbate hyperthyroidism.  Therapy with anticholinergics should be administered cautiously in patients with hyperthyroidism.  Thyroid levels should be monitored if usage is prolonged.

**Diarrhea** ğŸ”´ Major
- Diarrhea may be a symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy.  Antimuscarinic agents may further aggravate the diarrhea.  Therefore, these drugs should be administered cautiously in patients with ...

**Fever** ğŸ”´ Major
- Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.

**Heart Diseases** ğŸŸ¡ Moderate
- Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarizat...

*å¦æœ‰ 12 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
TxGNN é æ¸¬çš„é¦¬å°¾ç—‡å€™ç¾¤åŠç¥ç¶“æºæ€§è†€èƒ±é©æ‡‰ç—‡èˆ‡ Scopolamine çš„æŠ—è†½é¹¼ä½œç”¨æ©Ÿè½‰æœ‰ä¸€å®šé—œè¯ï¼Œ
ä½†ç›®å‰ç¼ºä¹è‡¨åºŠè©¦é©—åŠæ–‡ç»æ”¯æŒã€‚çµè†œç‚ç›¸é—œé æ¸¬å‰‡èˆ‡å·²çŸ¥æ©Ÿè½‰é—œè¯æ€§è¼ƒå¼±ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é‡å°ç¥ç¶“æºæ€§è†€èƒ±çš„è‡¨åºŠè©¦é©—æ•¸æ“š
- æ¢ç´¢ Scopolamine åœ¨é¦¬å°¾ç—‡å€™ç¾¤ç›¸é—œè†€èƒ±åŠŸèƒ½éšœç¤™çš„æ‡‰ç”¨
- è©•ä¼°é•·æœŸä½¿ç”¨çš„å®‰å…¨æ€§ï¼Œç‰¹åˆ¥æ˜¯èˆ‡å…¶ä»–æŠ—è†½é¹¼è—¥ç‰©ä½µç”¨æ™‚


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Methocarbamol]({{ "/drugs/methocarbamol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Leflunomide]({{ "/drugs/leflunomide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Xylitol]({{ "/drugs/xylitol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cephalexin]({{ "/drugs/cephalexin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Travoprost]({{ "/drugs/travoprost/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Scopolamineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/scopolamine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_scopolamine,
  title = {Scopolamineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/scopolamine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
